Get started
Author

Maelys Touya

Observed names: Maëlys Touya, Touya, Maëlys
Observed institution: Astellas Pharma (United States)
OpenAlex ID: A5084447985
Survival benefit associated with first-line androgen receptor pathway inhibitors for de novo metastatic castration-sensitive prostate cancer
2025 · Stephen J. Freedland, Agnes Hong, et al. · Prostate Cancer and Prostatic Diseases · 5
PDF
Clinical Outcomes and Treatment Patterns in Adults With FLT3-ITDmut+ Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the United States and Canada
2024 · Bhavik J. Pandya, Linda J. Burns, et al. · Transplantation and Cellular Therapy · 5
Work absenteeism, disability, and lost wages among patients with acute myeloid leukemia and their caregivers: a cohort study using US administrative claims and productivity data
2024 · Bhavik J. Pandya, Christopher Young, et al. · Expert Review of Pharmacoeconomics & Outcomes Research · 5
Real-world (RW) survival and outcomes with androgen receptor pathway inhibitor (ARPI) –doublet therapy in patients (pts) with de novo metastatic castration-sensitive prostate cancer (mCSPC).
2024 · Joshua Parrish, Thomas J. Polascik, et al. · Journal of Clinical Oncology · 3
PDF
How low do you need to go? Association between various prostate-specific antigen (PSA) response measures and clinical outcomes in metastatic castration-sensitive prostate cancer (mCSPC) in the Veteran Health Administration (VHA) data.
2025 · Stephen J. Freedland, Wei Gao, et al. · Journal of Clinical Oncology · 2
PDF
Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia – Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis
2025 · Amer M. Zeidan, Rebekah Yu, et al. · Acta Haematologica · 2
PDF
Outcomes with androgen-deprivation therapy (ADT) plus androgen receptor pathway inhibitors (ARPIs) in veterans with de novo metastatic castration-sensitive prostate cancer (mCSPC) who were elderly, frail, or had high comorbidity: A subgroup analysis of enzalutamide and high-volume disease.
2026 · Martin W. Schoen, Jason M. Doherty, et al. · Journal of Clinical Oncology · 1
Overall survival (OS) in elderly, frail, or high comorbidity veterans receiving androgen receptor pathway inhibitors (ARPIs) with androgen-deprivation therapy (ADT) vs ADT alone for de novo metastatic castration-sensitive prostate cancer (mCSPC).
2026 · Martin W. Schoen, Jason M. Doherty, et al. · Journal of Clinical Oncology · 1
PDF
Cardiovascular (CV) event risk in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) treated with enzalutamide (ENZA) or abiraterone acetate (AA) in the United States (US).
2025 · Alan Haruo Bryce, Maelys Touya, et al. · Journal of Clinical Oncology · 1
PDF
What criteria do clinicians use to classify men as “high risk” among patients with biochemically recurrent nonmetastatic castration-sensitive prostate cancer?
2024 · Stephen J. Freedland, Amanda Ribbands, et al. · Journal of Clinical Oncology · 1
Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer
2024 · Stephen J. Freedland, Amanda Ribbands, et al. · Advances in Therapy · 1
PDF
Real World Outcomes in Acute Myeloid Leukemia Patients Following Post Hematopoietic Stem-Cell Transplantation Maintenance Treatment with Midostaurin or Sorafenib: A US Retrospective Cohort Study
2022 · Lori Muffly, Christopher Young, et al. · Blood · 1
How low do you need to go? Association between various prostate‐specific antigen response measures and clinical outcomes in metastatic castration‐sensitive prostate cancer in the Veterans Health Administration data
2026 · Stephen J. Freedland, Wei Gao, et al. · Cancer
Real-World Treatment Patterns for Patients with High-Risk Biochemically Recurrent Nonmetastatic Castration‑Sensitive Prostate Cancer
2026 · Freedland, Stephen J., Ribbands, Amanda, et al. · PubMed Central
Ip73-05 Enzalutamide Versus Apalutamide in Metastatic Hormone-sensitive Prostate Cancer: a Real-world Study in a Urology Database
2026 · Martin W. Schoen, Maelys Touya, et al. · The Journal of Urology
Cardiotoxicity risk in metastatic castration-resistant prostate cancer: enzalutamide versus abiraterone
2026 · Alan H. Bryce, David Nimke, et al. · Cardio-Oncology
Real-world (RW) outcomes associated with enzalutamide (enza) vs apalutamide (apa) in metastatic castration-sensitive prostate cancer (mCSPC): Analysis of United States (US) oncology electronic health record (EHR) data.
2026 · Alicia K. Morgans, Maral DerSarkissian, et al. · Journal of Clinical Oncology
PDF
Corticosteroid Use and Risk of Adverse Events in Metastatic Hormone‐Sensitive Prostate Cancer
2026 · Umang Swami, Qiujun Shao, et al. · The Prostate
PDF
Does Physician Documentation of Patients’ Prostate-Specific Antigen Doubling Time Affect Treatment Decisions in High-Risk Biochemically Recurrent Prostate Cancer?
2026 · Alicia K. Morgans, Maelys Touya, et al. · Clinical Genitourinary Cancer
Evaluating overall survival with abiraterone acetate compared to enzalutamide in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer: Real-world data from the Flatiron electronic health records database.
2025 · Daniel J. George, Jasmina I. Ivanova, et al. · Journal of Clinical Oncology
Impact of physicians’ awareness of prostate-specific antigen doubling time (PSADT) on treatment (Tx) decisions in high-risk (HR) biochemically recurrent (BCR) prostate cancer (PC).
2025 · Alicia K. Morgans, Maelys Touya, et al. · Journal of Clinical Oncology
AML-177 Treatment Adherence and Persistence of FLT3 Inhibitors as Post-Allogenic Hematopoietic Cell Transplant Maintenance Therapy in Patients With Acute Myeloid Leukemia in the United States: A Cohort Study Using Administrative Claims Data
2024 · Vanessa E. Kennedy, Maelys Touya, et al. · Clinical Lymphoma Myeloma & Leukemia
Treatment Adherence and Persistence of FLT3 Inhibitors as Post-Allogenic Hematopoietic Cell Transplant Maintenance Therapy in Patients With Acute Myeloid Leukemia in the United States: A Cohort Study Using Administrative Claims Data
2024 · Vanessa E. Kennedy, Maelys Touya, et al. · Clinical Lymphoma Myeloma & Leukemia
POSTER: AML-197 Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)
2023 · Linda J. Burns, Bhavik J. Pandya, et al. · Clinical Lymphoma Myeloma & Leukemia
AML-197 Clinical Outcomes and Treatment Patterns in Adult Patients With FMS-Like Tyrosine Kinase 3 Internal Tandem Duplication Positive Acute Myeloid Leukemia Undergoing Allogeneic Hemopoietic Cell Transplantation in the US and Canada: CIBMTR® (Center for International Blood and Marrow Transplant Research Analysis)
2023 · Linda J. Burns, Bhavik J. Pandya, et al. · Clinical Lymphoma Myeloma & Leukemia
PDF
Works count: 27
Citation count: 28
H-index: 3
I10-index:
Year
Topic
Type